BD, 551153, BD Pharmingen™ Purified Mouse Anti-Human p16 with Control

Reactivity: Human (QC Testing)
Application: Western blot (Routinely Tested), Immunohistochemistry-frozen, Immunohistochemistry-paraffin, Immunoprecipitation (Tested During Development)
Regulatory Status: RUO
RRID: AB_394078
Description: Description Cyclins and cyclin-dependent kinases (cdks) form active complexes that regulate key events during the progression of the cell cycle and are evolutionarily highly conserved. The p16 protein has been identified as a specific inhibitor of cdk4 because it blocks cdk4 substrate phosphorylation. p16 inhibits cdk4 dependent phosphorylation of the tumor suppressor retinoblastoma protein (Rb) and Rb related proteins, p107 and p130. The biochemical properties of p16 suggest that it may be a tumor suppressor gene product. Recently a gene cloned from the short arm of human chromosome 9, Multiple Tumor Suppressor 1 (MTS1) has been identified as the gene for p16. The gene, now also known as the CDKN2 gene, has been found to be mutated in a very high percentage of tumors, including 75% of melanoma cell lines.
Preparation And Storage: Preparation And Storage The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store both the Purified Mouse Anti-Human p16 antibody (component 51-1325GR) and the HeLa control lysate (component 51-16516N) undiluted at -20°C.
Recommended Assay Procedures: Recommended Assay Procedures Western blot: For additional protocols on Western blotting, please refer to "Cell Biology (WB, IP, IHC, IF)" at our website: http://www.bdbiosciences.com/us/s/resources Endogenous p16 has been detected in several cell lines including Saos-2 human osteosarcoma (ATCC HTB-85), WI-38 human lung fibroblast (ATCC CCL-75), HeLa cervical carcinoma (ATCC CCL-2) and 293 adenovirus immortalized human kidney (ATCC CRL-1573) cells. U-2 OS human osteosarcoma (ATCC HTB-96) and MCF7 human breast carcinoma (ATCC HTB-22) have been reported to have undetectable levels of p16 and are suggested as negative controls. The differential tissue expression of p16 remains to be characterized by immunohistochemistry. Yeager et al.  has reported p16 to be both nuclear and cytoplasmic in melanoma.